Search Results - "Rodell, T C"

Xanthine oxidase-derived hydrogen peroxide contributes to ischemia reperfusion-induced edema in gerbil brains by PATT, A, HARKEN, A. H, LINAS, S. L, CHERONIS, J. C, REPINE, J. E, BURTON, L. K, RODELL, T. C, PIERMATTEI, D, SCHORR, W. J, PARKER, N. B, BERGER, E. M, HORESH, I. R, TERADA, L. S

“…The contribution of toxic O2 metabolites to cerebral ischemia reperfusion injury has not been determined. We found that gerbils subjected to temporary…”
Get full text

Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127 by Narotam, P K, Rodell, T C, Nadvi, S S, Bhoola, K D, Troha, J M, Parbhoosingh, R, van Dellen, J R

“…Focal cerebral contusions can be dynamic and expansive, leading to delayed neurological deterioration. Due to the high mortality associated with such cerebral…”
Get full text

Xanthine oxidase mediates elastase-induced injury to isolated lungs and endothelium by Rodell, T C, Cheronis, J C, Ohnemus, C L, Piermattei, D J, Repine, J E

“…Xanthine oxidase (XO)-generated toxic O2 metabolites appear to contribute to reperfusion injury, but the possibility that XO is involved in hyperoxic or…”
Get more information

The kallikrein/kinin system and kinin antagonists in trauma by Rodell, Timothy C.

“…These data and others indicate that the kallikrein/kinin system is activated in both systemic and central nervous system trauma and that specific kinin…”
Get full text

Pulmonary oxygen toxicity and ischemia-reperfusion injury. A mechanism in common involving xanthine oxidase and neutrophils by Repine, J E, Cheronis, J C, Rodell, T C, Linas, S L, Patt, A

Get more information

Endothelial cell xanthine oxidase-derived toxic oxygen metabolites contribute to acute lung injury from neutrophil elastase by Rodell, T C, Cheronis, J C, Repine, J E

Get more information

Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial by Cohn, A., Morse, M. A., O’Neil, B., Bellgrau, D., Duke, R. C., Franzusoff, A. J., Munson, S., Ferraro, J., Rodell, T. C.

“…Abstract only…”
Get full text

Mutation-selective tumor remission with ras-targeted, whole yeast-based immunotherapy by YINGNIAN LU, BELLGRAU, Donald, DWYER-NIELD, Lori D, MALKINSON, Alvin M, DUKE, Richard C, RODELL, Timothy C, FRANZUSOFF, Alex

“…Activating mutations in Ras oncoproteins represent attractive targets for cancer immunotherapy, but few vectors capable of generating immune responses required…”
Get full text

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis

“…To define the terms "sepsis" and "organ failure" in a precise manner. Review of the medical literature and the use of expert testimony at a consensus…”
Get more information

Yeasts encoding tumour antigens in cancer immunotherapy by Franzusoff, Alex, Duke, Richard C, King, Thomas H, Lu, Yingnian, Rodell, Timothy C

“…Immunotherapy for cancer represents an attractive therapeutic target because of its specificity and lack of toxicity, but products investigated so far have…”
Get more information

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group by Fein, A M, Bernard, G R, Criner, G J, Fletcher, E C, Good, Jr, J T, Knaus, W A, Levy, H, Matuschak, G M, Shanies, H M, Taylor, R W, Rodell, T C

“…To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic…”
Get full text

Traumatic brain contusions : A clinical role for the kinin antagonist CP-0127. Commentaries by NAROTAM, P. K, RODELL, T. C, NADVI, S. S, BHOOLA, K. D, TROHA, J. M, PARBHOOSINGH, R, VAN DELLEN, J. R, UNTERBERG, A, MAAS, A

Get full text

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP 0127) : Results of a randomized, double-blind, placebo-controlled trial by FEIN, A. M, BERNARD, G. R, RODELL, T. C, CRINER, G. J, FLETCHER, E. C, GOOD, J. T, KNAUS, W. A, LEVY, H, MATUSCHAK, G. M, SHANIES, H. M, TAYLOR, R. W

Get full text